Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
1
PTIX Quote, Financials, Valuation and Earnings
Last price:
$1.23
Seasonality move
:
-0.69%
Day range:
$1.19 - $1.31
52-week range:
$1.19 - $14.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.13x
P/B ratio:
1.61x
Volume:
49.6K
Avg. volume:
95.8K
1-year change:
-87.04%
Market cap:
$700.9K
Revenue:
--
EPS (TTM):
-$7.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PTIX
Protagenic Therapeutics, Inc.
|
-- | -- | -- | -- | -- |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.88 | -5.37% | -3.87% | $180.69 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PTIX
Protagenic Therapeutics, Inc.
|
$1.19 | -- | $700.9K | -- | $0.00 | 0% | 0.13x |
|
BIIB
Biogen, Inc.
|
$174.80 | $180.69 | $25.6B | 15.94x | $0.00 | 0% | 2.65x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.30 | $0.85 | $667.9M | 8.90x | $0.80 | 0% | 10.30x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.4M | -- | $0.00 | 0% | 0.33x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$6.75 | $11.75 | $398.9M | -- | $0.00 | 0% | 1.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PTIX
Protagenic Therapeutics, Inc.
|
-568.65% | 2.898 | 197.87% | 0.28x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PTIX
Protagenic Therapeutics, Inc.
|
-$12.6K | -$1.1M | -4551.84% | -- | -- | -$1.4M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Protagenic Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PTIX or BIIB?
Biogen, Inc. has a net margin of -- compared to Protagenic Therapeutics, Inc.'s net margin of 19%. Protagenic Therapeutics, Inc.'s return on equity of -- beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital PTIXProtagenic Therapeutics, Inc.-- -$0.47 -$703K BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About PTIX or BIIB?
Protagenic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 18723.52%. On the other hand Biogen, Inc. has an analysts' consensus of $180.69 which suggests that it could grow by 3.37%. Given that Protagenic Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Protagenic Therapeutics, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTIXProtagenic Therapeutics, Inc.0 0 0 BIIBBiogen, Inc.14 18 1 -
Is PTIX or BIIB More Risky?
Protagenic Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.228% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock PTIX or BIIB?
Protagenic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagenic Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTIX or BIIB?
Protagenic Therapeutics, Inc. quarterly revenues are --, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Protagenic Therapeutics, Inc.'s net income of -$869.5K is lower than Biogen, Inc.'s net income of $466.5M. Notably, Protagenic Therapeutics, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 15.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics, Inc. is 0.13x versus 2.65x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTIXProtagenic Therapeutics, Inc.0.13x -- -- -$869.5K BIIBBiogen, Inc.2.65x 15.94x $2.5B $466.5M
-
Which has Higher Returns PTIX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Protagenic Therapeutics, Inc.'s net margin of -255.85%. Protagenic Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PTIXProtagenic Therapeutics, Inc.-- -$0.47 -$703K NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PTIX or NBY?
Protagenic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 18723.52%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Protagenic Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Protagenic Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTIXProtagenic Therapeutics, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PTIX or NBY More Risky?
Protagenic Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.228% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock PTIX or NBY?
Protagenic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Protagenic Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTIX or NBY?
Protagenic Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Protagenic Therapeutics, Inc.'s net income of -$869.5K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Protagenic Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics, Inc. is 0.13x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTIXProtagenic Therapeutics, Inc.0.13x -- -- -$869.5K NBYNovaBay Pharmaceuticals, Inc.10.30x 8.90x $521K -$1.3M
-
Which has Higher Returns PTIX or PTN?
Palatin Technologies has a net margin of -- compared to Protagenic Therapeutics, Inc.'s net margin of --. Protagenic Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PTIXProtagenic Therapeutics, Inc.-- -$0.47 -$703K PTNPalatin Technologies-- -- -- -
What do Analysts Say About PTIX or PTN?
Protagenic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 18723.52%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Protagenic Therapeutics, Inc. has higher upside potential than Palatin Technologies, analysts believe Protagenic Therapeutics, Inc. is more attractive than Palatin Technologies.
Company Buy Ratings Hold Ratings Sell Ratings PTIXProtagenic Therapeutics, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is PTIX or PTN More Risky?
Protagenic Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.228% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock PTIX or PTN?
Protagenic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagenic Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTIX or PTN?
Protagenic Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Protagenic Therapeutics, Inc.'s net income of -$869.5K is higher than Palatin Technologies's net income of --. Notably, Protagenic Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics, Inc. is 0.13x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTIXProtagenic Therapeutics, Inc.0.13x -- -- -$869.5K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns PTIX or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Protagenic Therapeutics, Inc.'s net margin of --. Protagenic Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital PTIXProtagenic Therapeutics, Inc.-- -$0.47 -$703K TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About PTIX or TOVX?
Protagenic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 18723.52%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3570.69%. Given that Protagenic Therapeutics, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe Protagenic Therapeutics, Inc. is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTIXProtagenic Therapeutics, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is PTIX or TOVX More Risky?
Protagenic Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.228% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock PTIX or TOVX?
Protagenic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagenic Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTIX or TOVX?
Protagenic Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Protagenic Therapeutics, Inc.'s net income of -$869.5K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Protagenic Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics, Inc. is 0.13x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTIXProtagenic Therapeutics, Inc.0.13x -- -- -$869.5K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
-
Which has Higher Returns PTIX or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Protagenic Therapeutics, Inc.'s net margin of -40.15%. Protagenic Therapeutics, Inc.'s return on equity of -- beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital PTIXProtagenic Therapeutics, Inc.-- -$0.47 -$703K VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About PTIX or VNDA?
Protagenic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 18723.52%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 74.07%. Given that Protagenic Therapeutics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Protagenic Therapeutics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTIXProtagenic Therapeutics, Inc.0 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is PTIX or VNDA More Risky?
Protagenic Therapeutics, Inc. has a beta of 0.468, which suggesting that the stock is 53.228% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock PTIX or VNDA?
Protagenic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagenic Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTIX or VNDA?
Protagenic Therapeutics, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Protagenic Therapeutics, Inc.'s net income of -$869.5K is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Protagenic Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagenic Therapeutics, Inc. is 0.13x versus 1.87x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTIXProtagenic Therapeutics, Inc.0.13x -- -- -$869.5K VNDAVanda Pharmaceuticals, Inc.1.87x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
